U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H13ClN2O
Molecular Weight 284.74
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIAZEPAM

SMILES

CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3

InChI

InChIKey=AAOVKJBEBIDNHE-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479

Diazepam is a benzodiazepine first discovered at Hoffman-La Roche in the late 1950s. Diazepam was approved by FDA for the treatment of anxiety disorders as well as for such conditions as skeletal muscle spasm, alcohol withdrawal syndrom and convulsions (under the most known brand Valium). The drug acts by binding to GABA-A receptors and potentiating GABA evoked current. Chronic diazepam use is associated with tolerance, dependence, and withdrawal.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Palliative
VALIUM

Approved Use

Valium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

Launch Date

1963
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
317 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
75 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
172 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
208 ng/mL
20 mg single, intranasal
dose: 20 mg
route of administration: intranasal
experiment type: single
co-administered:
DIAZEPAM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1530 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
330 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
779 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1227 ng*h/mL
20 mg single, intranasal
dose: 20 mg
route of administration: intranasal
experiment type: single
co-administered:
DIAZEPAM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
48 h
unknown, oral
DIAZEPAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, oral
DIAZEPAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 28 years
Health Status: healthy
Age Group: 28 years
Sex: M
Sources:
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: F
Sources:
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Other AEs: Respiratory depression, Abuse...
Other AEs:
Respiratory depression (serious|grade 5)
Abuse (serious|grade 5)
Sources:
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Disc. AE: Somnolence, Hypoventilation...
AEs leading to
discontinuation/dose reduction:
Somnolence (3 patients)
Hypoventilation (2 patients)
Rash (2 patients)
Asthenia (1 patient)
Hyperkinesia (1 patient)
Incoordination (1 patient)
Vasodilatation (1 patient)
Urticaria (1 patient)
Sources:
10 mg 2 times / day multiple, intranasal
Recommended
Dose: 10 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (serious|grade 5)
Sources:
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Other AEs: Respiratory depression, Abuse...
Other AEs:
Respiratory depression (serious|grade 5)
Abuse (serious|grade 5)
Sources:
10 mg 4 times / day multiple, oral
Recommended
Dose: 10 mg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
OPIOIDS
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anxiety Disorders
Age Group: adult
Sources:
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (serious|grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abuse serious|grade 5
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Respiratory depression serious|grade 5
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Sources:
Asthenia 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Hyperkinesia 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Incoordination 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Urticaria 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Vasodilatation 1 patient
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Hypoventilation 2 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Rash 2 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Somnolence 3 patients
Disc. AE
0.2 mg/kg 2 times / day multiple, rectal
Recommended
Dose: 0.2 mg/kg, 2 times / day
Route: rectal
Route: multiple
Dose: 0.2 mg/kg, 2 times / day
Sources:
unhealthy, > 12 years
n = 573
Health Status: unhealthy
Condition: seizure activity
Age Group: > 12 years
Population Size: 573
Sources:
Respiratory depression serious|grade 5
10 mg 2 times / day multiple, intranasal
Recommended
Dose: 10 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Abuse serious|grade 5
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Respiratory depression serious|grade 5
10 mg 4 times / day multiple, intramuscular
Recommended
Dose: 10 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
benzodiazepines
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: anxiety disorders
Age Group: adult
Sources:
Respiratory depression serious|grade 5
10 mg 4 times / day multiple, oral
Recommended
Dose: 10 mg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg, 4 times / day
Co-administed with::
OPIOIDS
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anxiety Disorders
Age Group: adult
Sources:
OverviewDrug as perpetrator​Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
1975 Jan
[The mechanism of the anticonvulsive action of diazepam].
1975 Mar
Tetany, tetanus or drug reaction? A case report.
1976 Jul
Influence of adenosine agonists and antiepileptic drugs on theophylline-induced seizures in rats.
1998 Oct
Chlorambucil-induced seizure in a patient with nephrotic syndrome.
1999
Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.
1999 Dec
A fugue-like state associated with diazepam use.
1999 Jun
Anticonvulsants for soman-induced seizure activity.
1999 Mar-Apr
Syndrome of inappropriate secretion of antidiuretic hormone complicating neonatal diazepam withdrawal.
2000 Apr
The pharmacodynamics of PK 11195 in diazepam-dependent male and female rats.
2000 Aug
Acute adverse reaction to fentanyl in a 55 year old man.
2000 Aug
Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes.
2000 Aug
Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line.
2000 May 15
Negative inotropic effect of diazepam in isolated guinea pig heart.
2001 Feb
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo].
2001 Feb
Extracellular serotonin is enhanced in the striatum, but not in the dorsal hippocampus or prefrontal cortex, in rats subjected to an operant conflict procedure.
2001 Feb
Prenatal stress and postnatal development of neonatal rats--sex-dependent effects on emotional behavior and learning ability of neonatal rats.
2001 Feb
Regional and subunit-specific downregulation of acid-sensing ion channels in the pilocarpine model of epilepsy.
2001 Feb
Diazepam in the treatment of GHB dependence.
2001 Feb
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization.
2001 Feb 13
[Febrile convulsions, Treatment and prognosis].
2001 Feb 19
Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat.
2001 Feb 9
Evaluation of native GABA(A) receptors containing an alpha 5 subunit.
2001 Feb 9
[Anesthesia for a patient with cardiac sarcoidosis].
2001 Jan
Development of differential tolerance to the sedative and anti-stress effects of benzodiazepines.
2001 Jan
[Effect of diazepam on apnea attacks in a 6-year-old girl with Rett syndrome: a polysomnographic study].
2001 Jan
The octadecaneuropeptide ODN stimulates neurosteroid biosynthesis through activation of central-type benzodiazepine receptors.
2001 Jan
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.
2001 Jan
Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action.
2001 Jan 12
Long-term reduction of benzodiazepine receptor density in the rat cerebellum by acute seizures and kindling and its recovery 6 months later by a pentylenetetrazole challenge.
2001 Jan 12
In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466.
2001 Jan 26
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model.
2001 Mar
Trimethylolpropane phosphate induces epileptiform discharges in the CA1 region of the rat hippocampus.
2001 Mar 1
A behavioral economic analysis of polydrug abuse in alcoholics: asymmetrical substitution of alcohol and cocaine.
2001 Mar 1
Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test.
2001 Mar 2
The octadecaneuropeptide [diazepam-binding inhibitor (33-50)] exerts potent anorexigenic effects in rodents.
2001 Mar 2
Patents

Sample Use Guides

Tale 2-10 mg, 2 to 4 times daily.
Route of Administration: Oral
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/6722533
Rat brain membranes were treated with diazepam (1-1000 nM) and the drug was shown to enhance the effects of iontophoretically applied GABA.
Name Type Language
DIAZEPAM
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
VALTOCO
Brand Name English
RO 5-2807
Code English
DIAZEPAM [VANDF]
Common Name English
ANSIOLISINA
Common Name English
DIAZEPAM CIV
USP-RS  
Common Name English
VALIUM
Brand Name English
LA-III
Code English
DIAZEPAM [GREEN BOOK]
Common Name English
DIZAC
Brand Name English
SERVIZEPAM
Common Name English
DIAZEPAM [IARC]
Common Name English
RO-5-2807
Code English
DIAZEPAM [USAN]
Common Name English
DIASTAT
Brand Name English
NSC-77518
Code English
LA III
Code English
2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1,3-DIHYDRO-1-METHYL-5-PHENYL-
Systematic Name English
NSC-169897
Code English
DIAZEPAM [ORANGE BOOK]
Common Name English
RO-52807
Code English
7-CHLORO-1-METHYL-5-PHENYL-3H-1,4-BENZODIAZEPIN-2(1H)-ONE
Systematic Name English
DIAZEPAM [HSDB]
Common Name English
WY-3467
Code English
METHYL DIAZEPINONE
Systematic Name English
CENTRAZEPAM
Common Name English
Q-PAM
Brand Name English
7-CHLORO-1,3-DIHYDRO-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPINE-2-ONE
Systematic Name English
VALRELEASE
Brand Name English
DIAZEPAM [MART.]
Common Name English
DIACEPIN
Common Name English
Diazepam [WHO-DD]
Common Name English
DIAZEPAM [MI]
Common Name English
diazepam [INN]
Common Name English
DIAZEPAM [USP MONOGRAPH]
Common Name English
DIAZEPAM [JAN]
Common Name English
NRL-1
Code English
DIAZEPAM [EP MONOGRAPH]
Common Name English
DIAZEPAM CIV [USP-RS]
Common Name English
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Systematic Name English
TRANQUASE
Common Name English
Classification Tree Code System Code
NDF-RT N0000007542
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 384112
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
EPA PESTICIDE CODE 600069
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 334911
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 518316
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
LIVERTOX NBK548352
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-VATC QN05BA01
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 543516
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 638118
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 24.3
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 382512
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ATC N05BA01
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 05
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
DEA NO. 2765
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
NCI_THESAURUS C1012
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
FDA ORPHAN DRUG 61591
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
NDF-RT N0000175694
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1185008
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
MERCK INDEX
m4267
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY Merck Index
NSC
169897
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
RXCUI
3322
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY RxNorm
MESH
D003975
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
HSDB
3057
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
LACTMED
Diazepam
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DRUG BANK
DB00829
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID4020406
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DRUG CENTRAL
852
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
WIKIPEDIA
DIAZEPAM
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
EVMPD
SUB07069MIG
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
IUPHAR
3364
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
FDA UNII
Q3JTX2Q7TU
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
NCI_THESAURUS
C28982
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
INN
1295
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
CAS
439-14-5
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
PUBCHEM
3016
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL12
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
CHEBI
49575
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-122-5
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
SMS_ID
100000092362
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
DAILYMED
Q3JTX2Q7TU
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
NSC
77518
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIAZEPAM
Created by admin on Sat Dec 16 17:05:34 GMT 2023 , Edited by admin on Sat Dec 16 17:05:34 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; soluble in ethanol (~750 g/l) TS. Category: Tranquillizer. Storage: Diazepam should be kept in a well-closed container, protected from light. Definition: Diazepam contains not less than 99.0% and not more than 101.0% of C16H13ClN2O, calculated with reference to the dried substance.